Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 58

Sort by

Sort Order Select

Journal Articles

Lenalidomide Maintenance Does Not Negatively Impact Overall and Progression Free Survival Using Lenalidomide-Based Regimens for Multiple Myeloma in First Relapse

Hannah Cherniawsky, BSc,MD, Zack M. Breckenridge, BSc, Irwindeep Sandhu, MD FRCPC, Michael P. Chu, MD, Joanne D. Hewitt, NP, PhD, Ismail Ismail, Andrew R Belch, MD, Linda M. Pilarski, PhD, Tatiana Nikitina, Christopher P. Venner, MD FRCPC

Blood (2018) 132 (Supplement 1): 5643.

https://doi.org/10.1182/blood-2018-99-117705

Published: 2018

Journal Articles

MCRN ¯ 003/MYX · 1: A Single Arm Phase II Study of High-Dose Weekly Carfilzomib Plus Cyclophosphamide and Dexamethasone in the Treatment of Relapsed Multiple Myeloma after 1-3 Prior Therapies

Christopher P. Venner, MD FRCPC, Richard Leblanc, MDFRCPC, Irwindeep Sandhu, MDFRCPC, Darrell J. White, MD, Andrew R Belch, MD, Donna E Reece, MD, Christine I Chen, MD, Sean Dolan, MD, Andrea Kew, MDFRCP(C), Marc Lalancette, MD FRCP, Martha L Louzada, MD, Arleigh McCurdy, MD BSc, Gail T. McDonald, Tony Reiman, MD, Laura Rodriguez, Lois E. Shepherd, Engin Gul, BSc, Bingshu E. Chen, Annette E Hay

Blood (2018) 132 (Supplement 1): 1984.

https://doi.org/10.1182/blood-2018-99-117824

Published: 2018

Journal Articles

Indolent Non-Hodgkin Lymphoma: Skeletal Muscle Density Predicts Overall Survival With Rituximab Based Chemotherapy

Michael P Chu, MD, Jessica Lieffers, Andrew R Belch, MD, Neil Chua, MD, FRCPC, Amelie Fontaine, MD, Randeep Sangha, A. Robert Turner, MD, Sunita Ghosh, PhD, Michael Sawyer, MD

Blood (2013) 122 (21): 5078.

https://doi.org/10.1182/blood.V122.21.5078.5078

Published: 2013

Journal Articles

Initial Phase 3 Results Of The First (Frontline Investigation Of Lenalidomide + Dexamethasone Versus Standard Thalidomide) Trial (MM-020/IFM 07 01) In Newly Diagnosed Multiple Myeloma (NDMM) Patients (Pts) Ineligible For Stem Cell Transplantation (SCT)

Blood (2013) 122 (21): 2.

https://doi.org/10.1182/blood.V122.21.2.2

Published: 2013

Journal Articles

Final Report Of a Phase II Clinical Trial Of Lenalidomide Monotherapy For T-Cell Lymphoma

Ethan Toumishey, B. Sc, Angeli Prasad, CCRP, Gregory S. Dueck, MD, MSc, BSc, FRCPC, Neil Chua, MD, FRCPC, Daygen Finch, MD, Douglas A. Stewart, MD, FRCPC, Darrell J. White, MD, Richard H. van der Jagt, MD, FRCPC, James B Johnston, MD, Andrew R Belch, MD, Tony Reiman, MD

Blood (2013) 122 (21): 4376.

https://doi.org/10.1182/blood.V122.21.4376.4376

Published: 2013

Journal Articles

Aggressive Non-Hodgkin Lymphoma: Predictive Value Of Sarcopenia and Skeletal Muscle Density On Prognosis With Rituximab Containing Therapy

Michael P Chu, MD, Jessica Lieffers, Andrew R Belch, MD, Neil Chua, MD, FRCPC, Amelie Fontaine, MD, Randeep Sangha, A. Robert Turner, MD, FRCPC, Sunita Ghosh, PhD, Michael Sawyer, MD

Blood (2013) 122 (21): 3023.

https://doi.org/10.1182/blood.V122.21.3023.3023

Published: 2013

Journal Articles

Functional and Familial Risk of B Lineage Malignancies in Patients Carrying Single Nucleotide Polymorphisms (SNPs) in the Hyaluronan Synthase 1 Gene (HAS1),

Linda M. Pilarski, PhD, Hemalatha Kuppusamy, Jitra Kriangkum, PhD, Amanda Warkentin, Sunita Ghosh, PhD, Spencer B Gibson, PhD, Hlif Steingrimsdottir, MD, Vilhelmina Haraldsdottir, MD, James B Johnston, MD, FRCPC, Helga M Ogmundsdottir, MD, PhD, Andrew R Belch, MD

Blood (2011) 118 (21): 3930.

https://doi.org/10.1182/blood.V118.21.3930.3930

Published: 2011

Journal Articles

Clinically Significant Aberrant HAS1Vb Splicing of the Hyaluronan Synthase 1 Gene ( HAS1 ) Requires a Combination of Mutations and Deletions in Introns 3 and 4 of HAS1 Minigene,

Jitra Kriangkum, PhD, Andrew R Belch, MD, Linda M. Pilarski, PhD

Blood (2011) 118 (21): 3931.

https://doi.org/10.1182/blood.V118.21.3931.3931

Published: 2011

Journal Articles

Final Results From the Bortezomib-naïve Group of PX-171-004, a Phase 2 Study of Single-Agent Carfilzomib in Patients with Relapsed and/or Refractory MM

Blood (2011) 118 (21): 813.

https://doi.org/10.1182/blood.V118.21.813.813

Published: 2011

Journal Articles

A miRNA Risk Score for the Prediction of Response to Lenalidomide in Multiple Myeloma (MM) Patients

Paola Neri, MD, PhD, Andrew R Belch, MD, Jordan Johnson, Kathy J Gratton, Li Ren, PhD, Peter Duggan, MD, FRCPC, Adnan Mansoor, MD, FCPS, FRCP(C), FCAP, Douglas A. Stewart, MD, FRCP, Nizar Bahlis, MD

Blood (2011) 118 (21): 987.

https://doi.org/10.1182/blood.V118.21.987.987

Published: 2011

Journal Articles

Impact of Age on Outcomes Following Initial Therapy with Various Chemotherapy and Chemoimmunotherapy Regimens in Patients with Chronic Lymphocytic Leukemia (CLL): Results of CALGB Studies

Jennifer A. Woyach, MD, Amy S. Ruppert, MAS, Bercedis Peterson, PhD, MS, Kanti R. Rai, M.D., Thomas S. Lin, MD, PhD, Frederick R. Appelbaum, MD, Martin S. Tallman, MD, Andrew R Belch, MD, Richard A. Larson, MD, John C. Byrd, MD

Blood (2011) 118 (21): 289.

https://doi.org/10.1182/blood.V118.21.289.289

Published: 2011

Journal Articles

Patterns of Failure in Patients with Stage I/II Bulky Mediastinal Hodgkin Lymphoma (HL) Treated with ABVD + Radiotherapy or the Stanford V Regimen in the Randomized Phase III North American Intergroup Trial: E2496

Ranjana Advani, MD, Fangxin Hong, PhD, Leo I. Gordon, MD, FACP, Randy D. Gascoyne, MD, Henry Wagner, MD, Richard T. Hoppe, MD, Richard I Fisher, MD, Nancy L. Bartlett, MD, Brad S. Kahl, MD, Patrick Stiff, MD, Bruce D. Cheson, MD, Andrew R Belch, MD, Jonathan W. Friedberg, MD, MMSc, Jeannine Kassis, MD, Kristie A. Blum, MD, Thomas M. Habermann, MD, Joseph Tuscano, MD, Sandra J. Horning, MD

Blood (2011) 118 (21): 1603.

https://doi.org/10.1182/blood.V118.21.1603.1603

Published: 2011

Journal Articles

Splicing Profile of Human Hyaluronan Synthase 1 (HAS1) Is Altered by Mutagenesis of (A/U)GGG Motifs.

Jitra Kriangkum, PhD, Anirban Ghosh, PhD, Amanda A. Warkentin, BSc, Andrew R. Belch, MD, Linda M. Pilarski, PhD

Blood (2009) 114 (22): 2842.

https://doi.org/10.1182/blood.V114.22.2842.2842

Published: 2009

Journal Articles

Inherited and acquired variations in the hyaluronan synthase 1 ( HAS1 ) gene may contribute to disease progression in multiple myeloma and Waldenstrom macroglobulinemia

Sophia Adamia, Amanda A. Reichert, Hemalatha Kuppusamy, Jitra Kriangkum, Anirban Ghosh, Jennifer J. Hodges, Patrick M. Pilarski, Steven P. Treon, Michael J. Mant, Tony Reiman, Andrew R. Belch, Linda M. Pilarski

Blood (2008) 112 (13): 5111–5121.

https://doi.org/10.1182/blood-2008-02-141770

Published: 2008

Includes: Supplemental data

Journal Articles

A Population (Registry) Based Analysis of the Impact of Bcr-Abl Specific Tyrosine Kinase Inhibition on Survival after Diagnosis of Philadelphia Chromosome Positive Chronic Myelogenous Leukemia..

A. Robert Turner, MD, Joanne D Hewitt, BSN, NP, Anmmd Kamruzzaman, M.Sc, Loree M. Larratt, MD, Deborah A. Rusnak, BSN, Nanette Cox-Kennett, MSN, NP, Andrew R. Belch, MD

Blood (2008) 112 (11): 3237.

https://doi.org/10.1182/blood.V112.11.3237.3237

Published: 2008

Journal Articles

A unique three-dimensional model for evaluating the impact of therapy on multiple myeloma

Julia Kirshner, Kyle J. Thulien, Lorri D. Martin, Carina Debes Marun, Tony Reiman, Andrew R. Belch, Linda M. Pilarski

Blood (2008) 112 (7): 2935–2945.

https://doi.org/10.1182/blood-2008-02-142430

Published: 2008

Journal Articles

Analysis of clonotypic switch junctions reveals multiple myeloma originates from a single class switch event with ongoing mutation in the isotype-switched progeny

Brian J. Taylor, Jitra Kriangkum, Julie A. Pittman, Michael J. Mant, Tony Reiman, Andrew R. Belch, Linda M. Pilarski

Blood (2008) 112 (5): 1894–1903.

https://doi.org/10.1182/blood-2008-01-129221

Published: 2008

Journal Articles

Germline and Somatic Mutations in the Hyaluronan Synthase–1 (HAS1) Gene May Contribute to Oncogenesis in Multiple Myeloma (MM) and Waldenstrom’s Macroglobulinemia (WM).

Sophia Adamia, PhD, Amanda Reichert, Anirban Ghosh, Ph.D, Jennifer Hodges, Patrick Pilarski, Steven Treon, MD, Michael J. Mant, MD, Tony Reiman, MD, Andrew R. Belch, MD, Linda M. Pilarski, Ph.D

Blood (2007) 110 (11): 2488.

https://doi.org/10.1182/blood.V110.11.2488.2488

Published: 2007

Journal Articles

First Report of a Phase II Clinical Trial of Lenalidomide Oral Therapy for Peripheral T-Cell Lymphoma.

Tony Reiman, MD, Daygen Finch, MD, Neil Chua, MD, Darrell White, MD, Douglas A. Stewart, MD, Richard van der Jagt, MD, James Johnston, MD, Angeli Prasad, Henry Schwarz, Jerome Zeldis, MD, Andrew R. Belch, MD

Blood (2007) 110 (11): 2579.

https://doi.org/10.1182/blood.V110.11.2579.2579

Published: 2007

Journal Articles

Pre-Clinical Validation of Polo-Like Kinase 1 as a Therapeutic Target in Multiple Myeloma with the Selective Inhibitor BI2536.

Roger Sidhu, MD, Tara Steffler, Gail Hipperson, Michelle Jung, Joyce Fung, Linda M. Pilarski, PhD, Andrew R. Belch, MD, Tony Reiman, MD, MSc

Blood (2007) 110 (11): 2514.

https://doi.org/10.1182/blood.V110.11.2514.2514

Published: 2007

NARROW

Lenalidomide Maintenance Does Not Negatively Impact Overall and Progression Free Survival Using Lenalidomide-Based Regimens for Multiple Myeloma in First Relapse

MCRN ¯ 003/MYX · 1: A Single Arm Phase II Study of High-Dose Weekly Carfilzomib Plus Cyclophosphamide and Dexamethasone in the Treatment of Relapsed Multiple Myeloma after 1-3 Prior Therapies

Indolent Non-Hodgkin Lymphoma: Skeletal Muscle Density Predicts Overall Survival With Rituximab Based Chemotherapy

Initial Phase 3 Results Of The First (Frontline Investigation Of Lenalidomide + Dexamethasone Versus Standard Thalidomide) Trial (MM-020/IFM 07 01) In Newly Diagnosed Multiple Myeloma (NDMM) Patients (Pts) Ineligible For Stem Cell Transplantation (SCT)

Final Report Of a Phase II Clinical Trial Of Lenalidomide Monotherapy For T-Cell Lymphoma

Aggressive Non-Hodgkin Lymphoma: Predictive Value Of Sarcopenia and Skeletal Muscle Density On Prognosis With Rituximab Containing Therapy

Functional and Familial Risk of B Lineage Malignancies in Patients Carrying Single Nucleotide Polymorphisms (SNPs) in the Hyaluronan Synthase 1 Gene (HAS1),

Clinically Significant Aberrant HAS1Vb Splicing of the Hyaluronan Synthase 1 Gene ( HAS1 ) Requires a Combination of Mutations and Deletions in Introns 3 and 4 of HAS1 Minigene,

Final Results From the Bortezomib-naïve Group of PX-171-004, a Phase 2 Study of Single-Agent Carfilzomib in Patients with Relapsed and/or Refractory MM

A miRNA Risk Score for the Prediction of Response to Lenalidomide in Multiple Myeloma (MM) Patients

Impact of Age on Outcomes Following Initial Therapy with Various Chemotherapy and Chemoimmunotherapy Regimens in Patients with Chronic Lymphocytic Leukemia (CLL): Results of CALGB Studies

Patterns of Failure in Patients with Stage I/II Bulky Mediastinal Hodgkin Lymphoma (HL) Treated with ABVD + Radiotherapy or the Stanford V Regimen in the Randomized Phase III North American Intergroup Trial: E2496

Splicing Profile of Human Hyaluronan Synthase 1 (HAS1) Is Altered by Mutagenesis of (A/U)GGG Motifs.

Inherited and acquired variations in the hyaluronan synthase 1 ( HAS1 ) gene may contribute to disease progression in multiple myeloma and Waldenstrom macroglobulinemia

A Population (Registry) Based Analysis of the Impact of Bcr-Abl Specific Tyrosine Kinase Inhibition on Survival after Diagnosis of Philadelphia Chromosome Positive Chronic Myelogenous Leukemia..

A unique three-dimensional model for evaluating the impact of therapy on multiple myeloma

Analysis of clonotypic switch junctions reveals multiple myeloma originates from a single class switch event with ongoing mutation in the isotype-switched progeny

Germline and Somatic Mutations in the Hyaluronan Synthase–1 (HAS1) Gene May Contribute to Oncogenesis in Multiple Myeloma (MM) and Waldenstrom’s Macroglobulinemia (WM).

First Report of a Phase II Clinical Trial of Lenalidomide Oral Therapy for Peripheral T-Cell Lymphoma.

Pre-Clinical Validation of Polo-Like Kinase 1 as a Therapeutic Target in Multiple Myeloma with the Selective Inhibitor BI2536.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only